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The Journal of Immunology
Requirement of Inducible Nitric Oxide Synthase for Skeletal
Muscle Regeneration after Acute Damage
Elena Rigamonti,* Thierry Touvier,† Emilio Clementi,†,‡ Angelo A. Manfredi,*,x
Silvia Brunelli,*,{,1 and Patrizia Rovere-Querini*,1
Adult skeletal muscle regeneration results from activation, proliferation, and fusion of muscle stem cells, such as myogenic pre-
cursor cells. Macrophages are consistently present in regenerating skeletal muscles and participate into the repair process. The
signals involved in the cross-talk between various macrophage populations and myogenic precursor cells have been only partially
identified. In this study, we show a key role of inducible NO synthase (iNOS), expressed by classically activated macrophages in the
healing of skeletal muscle. We found that, after sterile injury, iNOS expression is required for effective regeneration of the tissue, as
myogenic precursor cells in the muscle of injured iNOS2/2 mice fail to proliferate and differentiate. We also found that iNOS
modulates inflammatory cell recruitment: damaged muscles of iNOS2/2 animals express significantly higher levels of chemokines
such as MIP2, MCP1, MIP-1a, and MCP1, and display more infiltrating neutrophils after injury and a persistence of macro-
phages at later time points. Finally, we found that iNOS expression in the injured muscle is restricted to infiltrating macrophages.
To our knowledge, these data thus provide the first evidence that iNOS expression by infiltrating macrophages contributes to
muscle regeneration, revealing a novel mechanism of inflammation-dependent muscle healing. The Journal of Immunology, 2013,
190: 1767–1777.
S
keletal muscle regeneration is an adaptive response to
injury or disease that involves the degeneration of damaged
myofibers and the activation of quiescent myogenic cells
that start to proliferate, differentiate, and fuse, leading to new
myofiber formation and reconstitution of a functional contractile
apparatus (1). It has become increasingly clear that inflammation
is critical for muscle regeneration (2) and that it has to be finely
tuned and eventually abated: persistent recruitment of inflamma-
tory cells and/or altered identity of the inflammatory infiltrate are
associated with functional impairment of the muscle healing re-
sponse (3).
Inflammation in acutely damaged muscle is characterized by
a rapid and sequential invasion of leukocytes that persists during
muscle repair, regeneration, and growth. Infiltrating leukocytes
play several roles that have not been completely characterized.
Neutrophils contribute to the early muscle membrane lysis fol-
lowing injury through a superoxide-dependent mechanism and
the release of myeloperoxidase (4, 5). Later on, macrophages
predominate: they remove necrotic debris and sustain the activa-
tion and the fusion of the myogenic precursor cells (6–9). Mac-
rophages that infiltrate the tissue at early stages after damage
produce cytokines and chemokines, including TNF-a and MCP-1.
At later stages they secrete trophic and anti-inflammatory cyto-
kines, such as insulin-like growth factor 1 (IGF-1) and IL-10,
which may sustain myofiber reconstitution. The actual role of the
various polarized infiltrating macrophages in the healing of the
injured muscle and by which signals they interact to this end with
myogenic stem cells has been to date poorly characterized.
NO is a key signaling molecule involved in adult skeletal muscle
homeostasis, including its regeneration after injury (10–13). In
particular, NO promotes myogenic precursor cell activation and
fusion and maintains the size of the pool of myogenic precursor
cells in acutely and chronically damaged muscles (14). NO is syn-
thesized from L-arginine by NO synthase (NOS) enzymes. Skeletal
muscle expresses the constitutive neuronal NOS (nNOS) (15) and
the endothelial NOS isoforms. The expression of the inducible
high throughput isoform (inducible NOS [iNOS]) has been re-
ported during embryonic muscle development, whereas in the
adult it occurs only in inflamed tissues. Previous studies have shown
that inhibition of all NOS isoforms jeopardizes muscle regenera-
tion (16, 17), as expected because of the obligatory role of NO in
skeletal muscle biogenesis and function. Likewise, ablation of
nNOS in myofibers or its functional impairment, as in Duchenne
muscular dystrophy, significantly reduces tissue repair. The spe-
cific contribution of iNOS to muscle healing has not been inves-
tigated yet. Because iNOS is expressed by specific macrophage
populations, understanding its function may shed light on the
mechanisms and role of inflammation in muscle repair. It may also
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add relevant information on the pathophysiology of muscle also
beyond repair, in those conditions such as cachexia and sarcope-
nia, in which iNOS is expressed.
In this study, we demonstrate that iNOS expression is re-
stricted to macrophages in the injured muscle and that iNOS
expression controls the homeostatic response to sterile injury by
regulating myogenic precursor cell function and shaping the
inflammatory infiltrate. To our knowledge, these data provide
the first evidence that iNOS-expressing macrophages play a
nonredundant role in the skeletal muscle repair after injury,
revealing a novel mechanism of inflammation-dependent mus-
cle healing.
Materials and Methods
Mice
Wild-type C57BL/6 mice (iNOS+/+) were purchased from Charles River
Laboratories (Calco, Italy), and mice carrying null mutation for iNOS
(B6.129P2-Nos2tm1Lau/J mice, iNOS2/2) were purchased from The Jack-
son Laboratory (Bar Harbor, ME). Null mutation of iNOS was confirmed
by PCR using an upstream primer that was common for both wild-type and
mutant DNA (59-ACATGCAGAATGAGTACCGG-39), a wild-type down-
stream primer (59-TCAACATCTCCTGGTGGAAC-39), and a downstream
primer for the neomycin cassette (59-AATATGCGAAGTGGACCTCG-39).
All procedures were performed in the animal facility of San Raffaele
Scientific Institute in accordance with European Union guidelines and with
the approval of the Institutional Ethical Committee.
FIGURE 1. iNOS is required for normal muscle regeneration after injury. (A–H) Representative images of TA muscle cross-sections from 2-mo-old
iNOS+/+ and iNOS2/2 mice at 3 (A, E), 5 (B, F), 7 (C, G), and 15 (D, H) d post-CTX injury, stained for H&E, original magnification320. Scale bar, 50 mm.
(I and J) Quantification of the number of centrally nucleated myofibers per mm2 in iNOS+/+ and iNOS2/2 regenerating muscles at 3 (I) and 5 (J) d after
injury (n = 5 mice per genotype). (K and L) Median CSA of myofibers from regenerating iNOS+/+ and iNOS2/2 TA muscles at 7 (K) and 15 (L) d postinjury.
Data pooled from .750 fibers from n = 5 mice per genotype. (M and N) Frequency histogram showing the distribution of myofiber CSA in the TA muscles
from iNOS+/+ and iNOS2/2 mice at 7 (M) and (N) 15 d postinjury. Bars indicate the mean 6 SD. *p , 0.05 versus iNOS+/+.
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FIGURE 2. iNOS2/2 mice display impaired myogenic precursor cell activation after muscle injury. (A, D–I) Immunofluorescence (IF) staining for Pax7
and MyoD on TA muscle sections from iNOS+/+ and iNOS2/2 mice at days 3, 5, 7, and 10 after CTX injection. (A) Quantification of the number of double-
positive Pax7+MyoD+ myogenic precursor cells on serial TA sections. Values shown are the results of experiments on three animals per group, mean6 SEM.
*p , 0.05 versus iNOS+/+. (D–I) Representative images of IF on TA sections from iNOS+/+ and iNOS2/2 mice 7 d after CTX injury, using Abs specific for
Pax7 (green; D, G) and MyoD (red; E, H). The superimposed images (overlay) of Pax7 and MyoD staining are shown (F, I) with the addition of Hoechst
staining for nuclei. Representative double-positive Pax7+MyoD+ myogenic precursor cells are indicated by arrows. Original magnification340. Scale bar, 50
mm. (B, J–O) Single muscle fibers were isolated from gastrocnemius muscles of 2-mo-old iNOS+/+ and iNOS2/2 mice 7 d after injury. Myogenic precursor
cells were coimmunostained for Pax7 and Ki67 using a double IF procedure. (B) Histogram representing the number of quiescent Pax7+Ki672 and activated
double-positive Pax7+Ki67+ myogenic precursor cells on iNOS+/+ and iNOS2/2 single myofibers. Data are expressed as mean 6 SEM, *p , 0.05 versus
iNOS+/+, and normalized for myofiber nuclei number. Results are from at least 50 fibers for each experiment, n = 3 per genotype. (J–O) Representative images
of iNOS+/+ and iNOS2/2 single fiber-associated myogenic precursor cells stained for Pax7 (green; J,M) and Ki67 (red; K, N) using a double IF procedure. The
superimposed images of Pax7 and Ki67 staining are shown (L, O), and representative double-positive proliferating myogenic (Figure legend continues)
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Acute muscle damage
iNOS+/+ and iNOS2/2 C57BL/6 mice were anesthetized and subsequently
injected with cardiotoxin (CTX; Naja mossambica mossambica, Sigma-
Aldrich; 50 ml, 15 mM for tibialis anterior [TA] muscles, 50 mM for
quadriceps muscles, or 25 mM for gastrocnemius muscles). Mice were
sacrificed at 1, 3, 5, 7, 10, and 15 d after injury. Injured muscles were
collected and snap frozen in liquid nitrogen for RNA and protein analyses.
For histology, muscles were collected and directly frozen in liquid
nitrogen-cool isopentane or fixed before in 4% paraformaldehyde (PFA)
and immersed sequentially in 10, 20, 30% sucrose.
Retrieval and purification of muscle-infiltrating inflammatory
leukocytes
Infiltrating cells were retrieved from damaged muscles at days 1, 3, 5, 7, and
10 after sterile injury.Muscles were dissociated by enzymatic digestion with
collagenase type V (Sigma-Aldrich; 0.5 mg/ml) and dispase (Invitrogen; 3.5
mg/ml) at 37˚C for 40 min. Infiltrating cells were further purified by
magnetic cell sorting using CD11b-conjugate beads (Milteny Biotec) and
processed for protein or RNA extraction. The purity of the retrieved cell
population, as verified by flow cytometry using a FACS CANTO (BD
Pharmingen) and the Flow Jo Software (Tree Star) after incubation with
a PerCP-conjugated anti-CD45 mAb (BD Pharmingen) and allophyco-
cyanin-conjugated anti-CD11b mAb (Clone BD Biosciences), was rou-
tinely .92%.
RNA extraction and quantitative real-time PCR analysis
Total RNAwas extracted from muscles or from purified muscle-infiltrating
CD11b+ cells using TRIzol reagent (Invitrogen), following manufacturer’s
recommendations. Total RNA (1 mg) was reverse transcribed with random
hexameric primers and MultiScribe reverse transcriptase (Applied Bio-
systems), as described (18). cDNAs were quantified by quantitative real-
time PCR on a MX 3000 apparatus (Stratagene) using specific primers for
Myogenin (59-GACATCCCCCTATTTCTACCA-39 forward; 59-GTCCC-
CAGTCCCTTTTCTTC-39 reverse), iNOS (59-AGCCAAGCCCTCACC-
TACTT-39 forward; 59-TCTCTGCCTATCCGTCTCGT-39 reverse), nNOS
(59-CTCACCCCGTCCTTTGAGTA-39 forward; 59-GGTCGCTTTGAC-
TCTCTTGG-39 reverse), endothelial NOS (59-GACCCTCACCGCT-
ACAACAT-39; 59-CTGGCCTTCTGCTCATTTTC-39 reverse), IGF-1
(59-GTGTGGACCGAGGGGCTTTTACTTC-39 forward; 59-GCTTCAG-
TGGGGCACAGTACATCTC-39 reverse), IL-10 (59-ATTTGAATTCCC-
TGGGTGAGAAG-39 forward; 59-CACAGGGGAGAAATCGATGACA-39
reverse), TNF-a (59-TCCCAGGTTCTCTTCAAGGGA-39 forward; 59-G-
GTGAGGAGCACGTAGTCGG-39 reverse), MIP-1a (59-CTGCCCTTGC-
TGTTCTTCTC-39 forward; 59-CCCAGGTCTCTTTGGAGTCA-39 reverse),
MIP2 (59-AGTGAACTGCGCTGTCAATG-39 forward; 59-TTCAGGGT-
CAAGGCAAACTT-39 reverse), MCP3 (59-AATGCATCCACATGCTGC-
TA-39 forward; 59-CTTTGGAGTTGGGGTTTTCA-39 reverse), MCP1 (59-
CCCAATGAGTAGGCTGGAGA-39 forward; 59-GCTAAGACCTTAGGG-
CAGA-39 reverse), 28S (59-AAACTCTGGTGGAGGTCCGT-39 forward;
59-CTTACCAAAAGTGGCCCACTA-39 reverse), cyclophilin A (59-CATA-
CGGGTCCTGGCATCTTGTCC-39 forward; 59-TGGTGATCTTCTTGCT-
GGTCTTGC-39 reverse). PCR amplification was performed in a volume of
20 ml containing 1 ml cDNA, 100 nmol/L of each primer, 4 mmol/L MgCl2,
the Brillant Quantitative PCR Core Reagent Kit mix, and SYBR Green
0.333. The conditions were 95˚C for 10 min, followed by 40 cycles of 30 s
at 95˚C, 30 s at 55˚C, and 30 s at 72˚C. The housekeeping gene 28S or
cyclophilin A was used for normalization.
Western blot analysis
Skeletal muscle and purified CD11b+ infiltrating cells were lysed in 10 mM
Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P40, 0.1% NaDodSO4 (SDS), 10
mM EDTA, and protease inhibitor mixture (Sigma-Aldrich). Lysates were
centrifuged at maximum speed for 15 min at 4˚C. For Western blot
analysis, equal amounts of protein (50 mg) were resolved by SDS-PAGE
and transferred onto Immobilon-P (Millipore). After Ponceau S (Sigma-
Aldrich) staining, membranes were saturated in 20 mM Tris-HCl (pH 7.6),
150 mM NaCl (TBS) containing 5% nonfat milk, and 0.1% Tween 20. Ags
were detected using rabbit polyclonal anti-mouse iNOS (1:400; Cell Sig-
naling), rabbit polyclonal anti-mouse nNOS (1:400; BD Transduction
Laboratories), rabbit polyclonal anti-mouse arginase I (1:1,000; Santa Cruz
Biotechnology), mouse monoclonal anti–b-actin (1:10,000; Sigma-Aldrich),
or mouse monoclonal anti-GAPDH (1:5,000; Sigma-Aldrich) Abs. All Abs
were diluted in TBST 5% nonfat milk. Bands were revealed using an ECL
detection kit (GE Healthcare Europe).
Histology
Muscle damage and repair were evaluated after H&E staining on 8-mm–
thick serial muscle sections. Fiber cross-sectional area (CSA) and central
nucleation analyses were carried out on 750–1000 fibers per muscle by
using Image J software (http://rsbweb.nih.gov/ij/). For immunofluores-
cence, sections were blocked with 5% BSA and 0.1% Triton in PBS before
incubation with rat polyclonal anti-CD11b (1:50; BD Pharmingen) and
rabbit polyclonal anti-iNOS Abs (1:100; Assay Designs) to identify
macrophages, or mouse monoclonal anti-Pax7 (1:2; Developmental Stud-
ies Hybridoma Bank) and rabbit polyclonal anti-MyoD Abs (1:25; Santa
Cruz Biotechnology) to identify myogenic precursor cells. Appropriate
Alexa Fluor (Alexa 488 or Alexa 594)-conjugated Abs (1:500; Invitrogen)
were used as second-step reagents. Specimens were counterstained with
Hoechst 33342 (Molecular Probes) and analyzed using a Nikon Eclipse 55i
microscope (Nikon). Images were captured with Digital Sight DS-5 M
digital camera (Nikon) using Lucia G software (Laboratory Imaging).
Pax7- and MyoD-expressing myogenic precursor cells were quantified
using ImageJ software. Immunohistochemistry was performed on muscle
sections fixed with 4% PFA treated with 0.3% H2O2 and with an avidin-
biotin blocking kit (Vector Laboratories), according to the manufacturer’s
instructions. Tissue sections were stained respectively with rat anti-mouse
Ly-6G (1:100; BioLegend) for neutrophils or rat anti-mouse CD68 mAb
(1:100; AbD Serotec), rabbit anti-mouse CD163 mAb (1:200; Santa Cruz
Biotechnology), and rat anti-mouse CD206 mAb (1:150; AbD Serotec) for
macrophages. Primary Abs were revealed using biotin-conjugated anti-rat
(1:300) or anti-rabbit (1:500) IgG (eBiosciences) and HRP streptavidin
(Vector Laboratories), and detected using Vector NovaRED substrate kit
(Vector Laboratories). Slides were counterstained with hematoxylin and
examined with a Nikon Eclipse 55i microscope (Nikon). Parallel slides
without primary Abs were identically processed and used as negative con-
trols. Results were quantified using ImageJ software.
Single fiber preparation and immunofluorescence
Gastrocnemius muscles of 2-mo-old iNOS+/+ and iNOS2/2 mice (three
animals of each genotype for experiments) were carefully dissected and
digested in 0.1% collagenase type V (Sigma-Aldrich). Individual myo-
fibers were dissociated, as described (14). Microscopic examination was
then performed to rule out contamination by capillaries. Myofibers were
fixed for 10 min in 4% PFA/PBS (Sigma-Aldrich) within 2 h. Myofibers
were subsequently washed with PBS and processed for immunofluorescence
using mouse monoclonal anti-Pax7 and/or rabbit anti-mouse Ki67 Abs (1:50;
Novocastra, Leica). Fibers were incubated in PBS containing 0.1% Triton X-
100 and 10% goat serum for 30 min and then challenged with PBS con-
taining 1% goat serum and the primary Ab overnight at 4˚C. Incubation with
the second-step reagent was carried out for 1 h at room temperature. Nuclei
were counterstained with Hoechst 33342, and samples were mounted on
slides using Gel-Mount aqueous mounting medium (Biomeda).
Isolation of primary myoblasts
Primary myoblasts from newborn iNOS+/+ and iNOS2/2 mice were iso-
lated, as described (19), and plated at clonal density. Cells were propagated
in proliferation medium (IMDM supplemented with 20% FBS, 3% chick
embryo, 100 U/ml penicillin, 100 mg/ml streptomycin, and 50 mg/ml
gentamicin) and subsequently shifted in differentiation medium (IMDM
supplemented with 2% horse serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin). After 24 and 48 h, cells were fixed with 4% PFA and
stained with anti-sarcomeric myosin MF20 mAb (1:2; Developmental
Studies Hybridoma Bank). Fusion index was determined as the number of
nuclei in sarcomeric myosin-expressing cells with more than two nuclei
versus the total number of nuclei.
precursor cells are indicated by arrows. Original magnification 320. Scale bar, 50 mm. (C) Time course changes in the expression of myogenin during
muscle regeneration. Skeletal muscles from iNOS+/+ and iNOS2/2 mice were collected immediately before and 1, 3, 7, and 10 d after injection of CTX and
totally lysated. mRNA levels of myogenin were quantified by real-time PCR analysis and normalized to 28S mRNA levels. Results are expressed as relative
fold changes compared with muscles from undamaged control animals (NT). Values shown are the results of experiments on six animals per group.
Statistically significant differences are indicated (ANOVA/t test, iNOS2/2 versus iNOS+/+; xp , 0.05, *p , 0.05 versus NT).
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FIGURE 3. iNOS expression is restricted to macrophages in skeletal muscle after acute damage. Quadriceps and TA muscles from 2-mo-old iNOS+/+
mice were collected immediately before and 1, 3, 7, 10, and 15 d after CTX injection. Muscles were totally lysated or digested to isolate CD11b+ cells by
magnetic bead sorting and processed for RNA or protein extraction. (A and C) Time course changes in the expression of iNOS (A) and nNOS (C) during
muscle regeneration were evaluated by real-time PCR. Results were normalized to 28S mRNA levels and expressed as relative fold changes compared with
undamaged muscles (NT). Bars indicate the mean 6 SEM, n = 6. *p , 0.05 versus NT. (B) Western blot analysis of iNOS and nNOS expression in total
healthy muscles and at different time points after CTX injection. Results are representative of five independent experiments. (D–F) Representative images
of IF on TA sections from 2-mo-old iNOS+/+ mice 3 d after CTX injury, using Abs specific for iNOS (red; D) and CD11b (green; E). The superimposed
images (overlay) of iNOS and CD11b staining are shown (F) with the addition of Hoechst staining for nuclei. iNOS-positive muscle-infiltrating CD11b+
macrophages are indicated by arrows. Original magnification 340. Scale bar, 50 mm. (G, H) iNOS and arginase I expression was analyzed in CD11b+ cells
retrieved from peripheral blood (CD11b+ CNT) or from muscles 1, 3, 5, 7, and 10 d after CTX injection by real-time PCR (G) (Figure legend continues)
The Journal of Immunology 1771
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Results
iNOS is required for efficient muscle regeneration in vivo
We compared muscles from age-matched iNOS+/+ and iNOS2/2
mice and found no significant difference in weight (data not
shown), morphology (Supplemental Fig. 1A, 1D), and myofiber
CSA (Supplemental Fig. 1B, 1C, 1E, 1F). These data indicate that
skeletal muscles of iNOS+/+ and iNOS2/2 mice do not substan-
tially differ in physiological conditions and that iNOS expression
is dispensable for the development and the physiology of the healthy
tissue. We then investigated the iNOS role in the tissue homeo-
static response to sterile injury. TA muscles of 2-mo-old iNOS+/+
and iNOS2/2 mice were injected with CTX, retrieved 3, 5, 7, and
15 d after damage, and processed for H&E staining (Fig. 1A–H).
Myofiber necrosis and massive infiltration of leukocytes and
regenerating centrally nucleated myofibers were detectable 3 d after
injury (Fig. 1A, 1E). At later time points (7, 15 d), infiltrating cells
progressively disappeared from the injured muscles of iNOS+/+
mice, and the diameter of regenerating fibers progressively in-
creased (Fig. 1C, 1D). In contrast, inflammatory cells persisted in
the injured tissues of iNOS2/2 mice and were preferentially dis-
tributed in the areas surrounding necrotic myofibers (Fig. 1G, 1H).
Regenerating myofibers were significantly less in iNOS2/2 in-
jured muscles (Fig. 1I, 1J) and smaller, as indicated by the CSA
analyses (Fig. 1K–N).
iNOS controls myogenic precursor cell early activation
We have investigated the function of myogenic precursor cells in
iNOS+/+ versus iNOS2/2mice by analyzing the expression of specific
myogenic markers. Pax7 is a transcription factor expressed by
quiescent and activated, but not differentiating, myogenic pre-
cursor cells. Upon activation, myogenic precursor cells start pro-
liferating, giving rise to Pax7+MyoD+ cells, which are committed
to differentiation. Myogenin is a transcription factor only expressed
by differentiating myogenic cells.
A progressive increase in the number of Pax7+ myogenic pre-
cursor cells that express the activation marker MyoD was de-
tectable by immunofluorescence in tissues of iNOS+/+ mice during
the first 7 d after injury, reflecting myogenic precursor cell acti-
vation and proliferation (Fig. 2A, 2D–F). By contrast, the num-
ber of activated Pax7+/MyoD+ myogenic precursor cells within
damaged areas of iNOS2/2 mice was initially lower while in-
creasing at later time points (7, 10 d) (Fig. 2A, 2G–I). Indeed, at
day 7 after damage, the number of myofiber-associated prolifer-
ating Pax7+/Ki67+ myogenic precursor cells in iNOS2/2 mice was
significantly higher than in iNOS-expressing counterparts (Fig.
2B, 2J–O). Moreover, the expression of myogenin, a marker of
myogenic precursor cell differentiation, was significantly lower at
day 3, while increasing at later time points (Fig. 2C). All together
these data indicate a role of iNOS in the early response of myo-
genic precursor cells to muscle injury in vivo, enabling them to
swiftly undergo activation, proliferation, and later on differentia-
tion. Of importance, single myofibers isolated from iNOS+/+ and
iNOS2/2 muscles before injury had similar numbers of associated
Pax7+/MyoD2 quiescent myogenic precursor cells (Supplemental
Fig. 2A–C), indicating that the myogenic precursor cell pool in the
two mouse lines does not substantially differ under physiological
conditions. Indeed, myogenic precursor cells isolated from iNOS+/+
or iNOS2/2 mice expanded with similar kinetics in vitro and fused
with similar efficiency (Supplemental Fig. 2D–F), making unlikely
that the phenotype we observed was due to a myogenic precursor
cell-autonomous defect. Because myogenic precursor cells do not
express iNOS (data not shown), the differences in iNOS-expressing
and deficient mice appear to depend on specific iNOS-dependent
signals originating during muscle repair by other cells.
Macrophages express iNOS in the injured/regenerating skeletal
muscle
iNOS mRNA and protein were barely detectable by real-time PCR
and Western blot analysis in healthy skeletal muscle (Fig. 3A, 3B).
iNOS expression increased 24 h after injury and persisted at 3 and
7 d, to decrease at later time points (Fig. 3A, 3B). nNOS had a
virtually opposite expression profile compared with iNOS; al-
though highly expressed in the healthy tissue (Supplemental Fig.
1G), where it is the most abundant NOS isoform, it disappeared
after muscle injury to become again detectable only at the later
time points (Fig. 3B, 3C). We then characterized the pattern of
iNOS expression by immunofluorescence in the injured and re-
generating tissue. We found that iNOS expression was restricted
to inflammatory leukocytes, identified by the expression of the
CD11b lineage marker (Fig. 3D–F). Moreover, we purified CD11b+
leukocytes by immunomagnetic bead sorting before and at various
time points after injury: iNOS was virtually absent before injury in
blood CD11b+ cells that represent the likely precursors of muscle-
infiltrating phagocytes, which in contrast abundantly expressed
the molecule 1, 3, and 5 d after damage (Fig. 3G, 3H). These data
identify phagocytes—initially neutrophils and from day 3 mac-
rophages (data not shown)—as the iNOS-expressing cells and
indicate that iNOS expression depends on specific cues associated
to the injured tissue. A similar expression profile was observed
for arginase 1, which uses the same substrate of NOS, L-arginine
(Fig. 3H).
iNOS shapes the recruitment of leukocytes and the production
of cytokines in the injured and regenerating muscle
Muscle injury and healing encompass the recruitment of inflam-
matory cells (20). We analyzed the role of iNOS-expressing
macrophages in shaping the inflammatory response during mus-
cle healing at 1, 3, 7, and 15 d after CTX injection. At day 1 after
injury, neutrophil infiltration was significantly higher in the
injured muscle of iNOS2/2 than in those of iNOS+/+ mice, as
assessed by the immunohistochemical analysis of the neutrophil
surface marker Ly-6G (Fig. 4A–C), thus indicating that iNOS
expression quenches the infiltration of neutrophils at sites of in-
jury. Infiltration by CD68+ macrophages was significantly more
important in muscles of iNOS+/+ mice than iNOS2/2 littermates at
1 and 3 d after injury (Fig. 4C, 4D, 4G, 4J). This effect was
transient because 7 and 15 d after injury macrophages disappeared
from the tissues of wild-type animals while increasing in iNOS2/2
muscles (Fig. 4C, 4H, 4I, 4K, 4L). A fraction of CD68+ macro-
phages also expressed the haptoglobin/hemoglobin scavenger re-
ceptor, CD163, and the mannose receptor, CD206, two markers of
alternatively activated cells (data not shown). Interestingly, iNOS
did not detectably influence the expression of these markers, as
assessed by quantitative analyses of muscle serial sections (Fig.
4E, 4F).
and by Western blot analysis (H). (G) mRNA levels of iNOS were normalized to 28S mRNA levels and expressed as relative fold changes compared with
CD11b+ cells retrieved from peripheral blood (CD11b+ CNT). Bars indicate the mean 6 SD, n = 3 mice per three independent experimental cohorts. *p ,
0.05 versus CD11b+ CNT. (H) Results are representative of three independent preparations. In vitro polarized IFN-g (M1) and IL-10 (M2) macrophages
were used as internal control.
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FIGURE 4. Muscle inflammatory infiltrate is perturbed in iNOS2/2 after acute damage. Muscle infiltration of neutrophils and macrophages 1 d after
CTX injection was detected by immunohistochemical (IHC) staining with specific Abs respectively for Ly-6G (A–C) and CD68 (C) on TA muscle sections
of iNOS+/+ and iNOS2/2 mice. (A and B) Images are representative of four independent experiments. Original magnification 320. Scale bar, 50 mm. (C)
Quantification of the number of positive cells on serial TA sections. Values shown are the results of experiments on four animals per group, mean 6 SD,
*p , 0.05 versus iNOS+/+. (D–L) Macrophage infiltration in muscle sections of iNOS+/+ and iNOS2/2 mice at days 3, 7, and 15 from CTX injection. The
number of CD68 (D)-, CD163 (E)-, and CD206 (F)-positive cells was assessed on serial TA muscle section at the indicated time points. Values shown are the
results of experiments on four animals per group, mean 6 SEM, *p, 0.05 versus iNOS+/+. (G–L) Representative images of TA muscle cross-sections from
2-mo-old iNOS+/+ and iNOS2/2 mice at 3 (G, J), 7 (H, K), and 15 (I, L) days post-CTX injury, immunostained for CD68. Original magnification 310. Scale
bar, 100 mm. (M–O) Time course changes in expression of IGF-1, IL-10, and TNF-a during muscle regeneration. Muscles from (Figure legend continues)
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To investigate the mechanism through which iNOS acts, we
analyzed the expression of selected growth factors, cytokines, and
chemokines that have been associated with the preferential tissue
infiltration by inflammatory cells. Real-time PCR analyses revealed
that the expression of IGF-1 in iNOS+/+ muscles was upregulated
after injury (3, 7 d) to decrease at later time points (day 10), whereas
in iNOS2/2 counterparts IGF-1 mRNA increase was significantly
lower, but persistent (Fig. 4M). IL-10 expression was increased
between day 1 and 10 after injury in the muscles of both iNOS+/+
and iNOS2/2 mice. IL-10 mRNA levels were always significantly
higher in iNOS2/2 injured muscles (Fig. 4N). No difference was
observed in TNF-a expression between iNOS+/+ and iNOS2/2
muscles (Fig. 4O).
The expression of (MIP)-1a, MIP2, MCP1, and MCP3 was up-
regulated in injured muscles of iNOS+/+ mice at days 1 and 3 after
damage (Fig. 5A–D), to abate at later time points. Expression of
MIP2, a potent chemoattractant and activator of neutrophils, was
significantly higher in iNOS2/2 muscles (Fig. 5A) and infiltrating
leukocytes (Fig. 5E). Early after injury, iNOS2/2 muscles and
leukocytes displayed less MCP1 mRNA levels (Fig. 5B, 5F).
Expression of MIP-1a and MCP3, involved in both macrophage
and neutrophil recruitment, was significantly higher in iNOS2/2
injured muscles (Fig. 5C, 5D) and infiltrating CD11b+ leukocytes
(Fig. 5G, 5H) at all the analyzed time points. These results suggest
that macrophage iNOS acts as an early homeostatic regulator of
inflammatory leukocyte recruitment.
Discussion
The regeneration of injured muscle involves a complex and tightly
regulated interaction between inflammatory cells recruited into the
injured tissue and myogenic precursor cells. Macrophages pre-
dominate in damaged and regenerating muscle. They have been
known for a long time to be associated with skeletal muscle injury
(21, 22), and in vivo studies have unequivocally shown that they
actually participate in the tissue repair process (7, 18, 23–28).
Although several molecules have been identified to be dispensable
for muscle regeneration, the overall array of signals that mac-
rophages deliver in the tissue and the hierarchy among them is
far from being elucidated.
To our knowledge, the present study provides the first evidence
that iNOS contributes to muscle regeneration after injury, re-
vealing a novel mechanism of inflammation-dependent muscle
healing. We found that injured muscles of iNOS-deficient mice
display impaired muscle regeneration, as indicated by decreased
number and size of new regenerating centrally nucleated myofibers
and persistence of the inflammatory infiltrate. We demonstrated that
iNOS is barely expressed in healthy skeletal muscle, but is selec-
tively induced in inflammatory macrophage-infiltrating muscle at
early stages after acute injury.
Interestingly, we found that nNOS, the primary isoform of NOS
in skeletal muscle, displays an opposite expression profile com-
pared with iNOS. After muscle injury, nNOS almost completely
disappears and is only again detectable at late time points of the
regeneration process. Notably, NO plays a nonredundant role in
muscle repair after injury by promoting activation, differentiation,
and fusion of myogenic precursor cells (10, 29–34). Thus, a source
of NO appears necessary for an efficient muscle repair. The
present study identifies iNOS, expressed by infiltrating macro-
phages, as the isoform that provides this NO in the early phases of
muscle regeneration. We found that after muscle damage the in-
crease of double-positive activated Pax7+MyoD+ myogenic pre-
cursor cells is significantly delayed in iNOS-deficient mice compared
with wild-type littermates. Activation and subsequent proliferation
and terminal differentiation of these cells drive muscle repair
through fusion with damaged muscle fibers or with themselves,
to produce new fibers (35, 36). Consistently, in injured muscles of
iNOS-deficient mice, the expression of myogenin, a marker of
differentiation of these myogenic precursor cells, is significantly
lower than in those of wild-type mice. All together, our data
suggest a critical role of iNOS-derived NO in muscle regener-
ation. These results may explain why genetic deletion of nNOS
does not impair functional muscle regeneration after myotoxic
injury (37).
Our results point to another critical role of iNOS in muscle
regeneration: the modulation of the inflammatory response. Several
studies indicated that iNOS-derived NO is an important homeo-
static regulator of leukocyte recruitment in the inflamed micro-
circulation, suggesting that one of its functions may be to act as an
endogenous anti-inflammatory molecule during ongoing inflam-
mation (38). Accordingly, in several inflammatory models, iNOS-
deficient mice have difficulty in resolving the inflammation, and
neutrophil infiltration persisted for several days longer than in
wild-type mice (39). Interestingly, we found that after muscle
damage iNOS2/2mice display a greater accumulation of neutrophils
and fewer macrophages. Consistently, comparing damaged mus-
cles and muscle-infiltrating macrophages of iNOS-deficient mice
with those of wild-type mice, we found higher expression levels of
chemokines associated with neutrophil infiltration, such as MIP-
1a, MIP2, and MCP3. Thus, it is likely that these chemokines
account for the significant increase of neutrophil accumulation in
iNOS-deficient mice. Neutrophils release molecules that may
contribute to muscle membrane lysis that follows injury. In vivo
neutrophil accumulation in muscle after exercise coincides with
disruption in myofibril structure (4), and in the presence of bac-
terial endotoxin the cytotoxic potential of neutrophils significantly
increases, thus resulting in enhanced tissue damage and delayed
regeneration (40). As such, neutrophil accumulation in iNOS2/2
muscles 1 d after damage may contribute to impaired muscle healing.
Of note, genetic disruption of the CXCL16 chemokine pathway
results in a persistent and important infiltration of injured muscle
by neutrophils, defective homing of macrophages, and severely
jeopardized tissue regeneration (41).
Interestingly, we found that, in iNOS2/2 injured muscles,
macrophage recruitment is delayed, but macrophages persist lon-
ger as compared with wild-type counterparts. At 1 and 3 d after
damage, iNOS2/2 muscles display a decreased macrophage in-
filtration. Consistently, MCP1, a potent chemoattractant and ac-
tivator of macrophages, was significantly reduced in damaged
muscles and muscle-infiltrating macrophages of iNOS2/2 mice.
However, at 7 and 15 d after damage, macrophages were still
significantly present in the muscles of iNOS2/2 mice. Persistence
of macrophages could potentially derive from the extended pres-
ence of necrotic tissue in iNOS2/2 mice. Of note, macrophages
are critical to the removal of necrotic tissue (42) and together with
myogenic precursors and injured fibers are a source of chemokines
(6, 43). Accordingly, another mechanism that may contribute to
iNOS+/+ and iNOS2/2 mice were collected immediately before and 1, 3, 7, and 10 d after injection of CTX and totally lysated. mRNA levels of IGF-1 (M),
IL-10 (N), and TNF-a (O) were quantified by real-time PCR analysis and normalized to 28S mRNA levels. Results are expressed as relative fold changes
compared with muscles from undamaged control animals (NT). Values shown are the results of experiments on six animals per group. Statistically sig-
nificant differences are indicated (ANOVA/t test; iNOS2/2 versus iNOS+/+; xp , 0.05, *p , 0.05 versus NT).
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FIGURE 5. Chemokine expression profile in injured iNOS+/+ muscles differs from the pattern in the muscles of iNOS2/2 mice. Quadriceps and TA
muscles from 2-mo-old iNOS+/+ and iNOS2/2 mice were collected immediately before and 1, 3, 5, and 7 d after injection of CTX. Muscles were totally
lysated or digested to isolate CD11b+ cells by magnetic bead sorting and processed for RNA extraction. Real-time PCR analyses for MIP2, MCP1, MIP-1a,
and MCP3 mRNA expression respectively in total muscle (A–D) and in muscle-infiltrating CD11b+ cells (E–H) were performed. Results were normalized to
28S mRNA levels and expressed as relative fold changes compared with undamaged muscles (NT) (A–D) or to CD11b+ cells retrieved from peripheral
blood (CD11b+ CNT) (E–H). (A–D) Values shown are the results of experiments on six animals per group. (E–H) Bars indicate the mean 6 SD, n = 3 mice
per three independent experimental cohorts. Statistically significant differences are indicated (ANOVA/t test; iNOS2/2 versus iNOS+/+; xp , 0.05, *p ,
0.05 versus NT or CD11b+ CNT).
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the persistence of macrophages includes alterations in the pro-
duction of macrophage chemoattractants in the iNOS2/2 damaged
muscles. Support for this possibility derives from the significantly
elevated MIP-1a and MCP3 levels in iNOS2/2 macrophage-
infiltrating muscle at 5 and 7 d after damage. To our knowledge,
these findings provide the first evidence that in damaged muscle
iNOS-derived NO can act as a homeostatic regulator of inflam-
matory leukocyte recruitment.
In conclusion, to our knowledge, we provide the first evidence of
a critical role of iNOS in muscle regeneration. Our results identify
iNOS-derived NO as a key messenger in regulating myogenic
precursor cell fate and the inflammatory response in a model of
muscle damage/regeneration, thus revealing a novel mechanism of
inflammation-dependent muscle healing. This information may be
used to finely tune therapies based on NO donation and regulation
of inflammation that appear to be effective in healing muscle
damage after acute or prolonged injury (44–47).
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